-
Founded in:
1993-01-09 -
Country:
China -
Address:
No. 68, Jianye Road, Liangqing District, Nanning City, Guangxi -
Tax NO.:
914500006193013418 -
Registered Funds:
50 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bupleurum |
|
0 | ||
| RADIX SCUTELLARIAE |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| NOTOGINSENG RADIX ET RHIZOMA |
The maximum dosage of Guanxin Danshen Tablets for oral administration twice a day is 853 tablets/kg. It has low acute toxicity and is safe to use.
More
The maximum dosage of Guanxin Danshen Tablets for oral administration twice a day is 853 tablets/kg. It has low acute toxicity and is safe to use. |
0 | ||
| Salvia Root P.E Tanshinone IIA 20% |
The maximum dosage of Guanxin Danshen Tablets for oral administration twice a day is 853 tablets/kg. It has low acute toxicity and is safe to use.
More
The maximum dosage of Guanxin Danshen Tablets for oral administration twice a day is 853 tablets/kg. It has low acute toxicity and is safe to use. |
0 | ||
| Costus oil |
The maximum dosage of Guanxin Danshen Tablets for oral administration twice a day is 853 tablets/kg. It has low acute toxicity and is safe to use.
More
The maximum dosage of Guanxin Danshen Tablets for oral administration twice a day is 853 tablets/kg. It has low acute toxicity and is safe to use. |
8023-88-9 | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clematis |
|
0 | ||
| Ephedra |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gliclazide |
This product is a second-generation sulfonylurea hypoglycemic drug with a strong effect. Its mechanism is to selectively act on pancreatic islet b cells, promote insulin secretion, and increase insulin release after eating glucose, so that the production and output of glycogen are inhibited. This product has been proven through animal experiments and clinical use to reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy.
More
This product is a second-generation sulfonylurea hypoglycemic drug with a strong effect. Its mechanism is to selectively act on pancreatic islet b cells, promote insulin secretion, and increase insulin release after eating glucose, so that the production and output of glycogen are inhibited. This product has been proven through animal experiments and clinical use to reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy. |
21187-98-4 | 23 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Palmflower seeds |
|
0 | ||
| Camptotheca acuminata reference medicinal material |
|
0 | ||
| Zedoary turmeric |
|
0 | ||
| Astragali Radix |
|
0 |